Table of contents
- Clinical trial overview
- Who the study is for
- Trial phase and study design
- What the researchers are measuring
- RP3 and related RPx products
- Key points for patients
Clinical trial overview
The available trial for RP3 is an interventional study, which means participants were followed as part of a planned research program.[1] The study is authorised and has 76 planned participants.[1]
This trial is designed to evaluate long-term safety after treatment with RP3 or related RPx products.[1] The brief summary says the goal is to identify delayed adverse events linked to treatment.[1]
Who the study is for
The study includes patients with metastatic melanoma, advanced solid tumors, hepatocellular carcinoma, and melanoma.[1] These are cancer groups that reflect the target population in the trial data.[1]
The trial title states that the patients had been previously treated with RP1, RP2, or RP3.[1] That means the study is focused on people after earlier treatment, not on first-time use.[1]
Trial phase and study design
This study is in Phase 3.[1] Phase 3 trials are later-stage studies that usually include more patients and help researchers learn more about safety in a wider group.[1]
The study uses RP3 and related RPx products given by intratumoral use, which means the product is placed directly into the tumor.[1] The source data list RP3, RP2, and vusolimogene oderparepvec in the intervention field.[1]
What the researchers are measuring
The main outcome is the evaluation of delayed adverse events.[1] These are side effects or health problems that appear later, after treatment has already been given.[1]
Researchers are looking for several specific problems, including new malignancies, worsening or new neurologic disorders, rheumatologic or other autoimmune disorders, hematologic disorders, infection related to RPx, and herpetic infection.[1] They are also checking for the presence of RPx in samples collected from herpetic lesions.[1]
New malignancy: a new cancer that appears during follow-up.[1]
Neurologic disorder: a problem affecting the brain, nerves, or spinal cord.[1]
Autoimmune disorder: a condition where the immune system attacks the body’s own tissues.[1]
Hematologic disorder: a blood-related problem.[1]
Herpetic infection: infection linked to herpes viruses.[1]
RP3 and related RPx products
The trial title and summary refer to RP1, RP2, RP3, and the group name RPx products.[1] In the source data, these products are grouped together for long-term safety follow-up.[1]
The source material does not provide a deeper description of how RP3 works, so this article stays focused on the clinical trial goals and patient groups.[1]
Key points for patients
The available RP3 study is focused on safety after earlier treatment.[1]
It includes patients with several cancer types, especially melanoma-related conditions and liver cancer.[1]
The study is in Phase 3 and is already authorised.[1]
Researchers are mainly watching for delayed side effects and late health problems.[1]
